This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
by Zacks Equity Research
The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
by Zacks Equity Research
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?
by Kinjel Shah
JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
by Sundeep Ganoria
VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.
Lilly Loses Around $14B This Week: How to Play LLY Stock
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR
by Zacks Equity Research
Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top Analyst Blog.
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
by Sanghamitra Saha
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.
FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List
by Zacks Equity Research
The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
AZN or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AZN vs. NVO: Which Stock Is the Better Value Option?
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
by Zacks Equity Research
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
Implied Volatility Surging for Novo Nordisk (NVO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Novo Nordisk (NVO) stock based on the movements in the options market lately.
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $117.20, moving -0.48% from the previous trading session.
Pfizer Receives $1 Billion From Starboard Value, Stock Rises
by Zacks Equity Research
PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
by Zacks Equity Research
Lilly is investing $4.5 billion to build a new site for improving manufacturing and drug development.
Novo Nordisk (NVO) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $118.01, denoting a -0.89% change from the preceding trading day.
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
by Zacks Equity Research
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
by Zacks Equity Research
2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.
The Zacks Analyst Blog Highlights Broadcom, Novo Nordisk, ConocoPhillips, Smith-Midland Corp. and Tredegar
by Zacks Equity Research
Broadcom, Novo Nordisk, ConocoPhillips, Smith-Midland Corp. and Tredegar are part of the Zacks top Analyst Blog.